Laparoscopic Ovarian Drilling for PCOS: Success Rate vs Risks

What Is Laparoscopic Ovarian Drilling, and How Does It Work?

Laparoscopic ovarian drilling (LOD) is a keyhole procedure, done under general anaesthesia, in which a surgeon makes a small number of punctures — typically four to ten per ovary — into the ovarian surface and stroma using diathermy (electrocautery) or laser. The goal is to destroy a portion of the androgen-producing ovarian stroma, which in PCOS drops circulating androgens and luteinising hormone (LH) enough, in some women, to restart spontaneous ovulation without medication. It is the minimally invasive descendant of open ovarian wedge resection, a technique that worked but was abandoned decades ago for causing extensive pelvic adhesions once a medical alternative existed.

LOD is not a first-line fertility treatment and is not studied as one. Every trial cited here enrolled women with anovulatory PCOS who had already failed to ovulate on clomiphene citrate — the population the 2023 international guideline addresses when it names laparoscopic ovarian surgery a second-line option, alongside gonadotropins, for clomiphene-resistant PCOS with no other infertility factor. What “clomiphene-resistant” means, and what a clinician checks before applying that label, is covered on the clomiphene page; this page picks up from there.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same surgical evidence — only the label changed. This article uses PCOS, since that is still the term most readers search.

What Are the Actual Success Rates for Laparoscopic Ovarian Drilling?

Live birth rates were slightly lower with LOD than with medical ovulation induction alone, across a 2020 Cochrane review pooling 38 randomised trials involving 3,326 women with clomiphene-resistant anovulatory PCOS — an odds ratio of 0.71 (95% CI 0.54 to 0.92) from 9 of those trials totalling 1,015 women, rated low-quality evidence. In practical terms, the review states that if the chance of a live birth on medical induction alone is 42%, the chance following LOD would fall somewhere between 28% and 40%. That headline finding softens considerably on closer inspection: restricting the analysis to only the trials at low risk of bias left genuine uncertainty about whether any difference exists at all (OR 0.90, 95% CI 0.59 to 1.36; 4 trials, 415 women). Clinical pregnancy showed little or no difference either way (OR 0.86, 95% CI 0.72 to 1.03; 21 trials, 2,016 women), and miscarriage risk was likewise uncertain (OR 1.11, 95% CI 0.78 to 1.59; 19 trials, 1,909 women).

Two outcomes did move clearly in LOD’s favour. Multiple pregnancy was substantially less common after LOD (Peto OR 0.34, 95% CI 0.18 to 0.66; 14 trials, 1,161 women) — the review estimates that a 5.0% multiple-pregnancy rate on medical induction would fall to somewhere between 0.9% and 3.4% after LOD — and ovarian hyperstimulation syndrome, already rare with either approach, may be lower still after LOD (Peto OR 0.25, 95% CI 0.07 to 0.91; 8 trials, 722 women).

How Does Ovarian Drilling Compare With Gonadotropins Specifically?

Ongoing pregnancy at 12 months reached 67% whether women were assigned to gonadotropin injections from the start or to an electrocautery-first strategy, in a randomised trial of 168 women with clomiphene-resistant PCOS conducted across secondary and tertiary hospitals in the Netherlands. In that trial, electrocautery alone produced an ongoing pregnancy rate of 34%, rising to 49% once clomiphene was added back in for women who remained anovulatory, and reaching the same 67% as the gonadotropin-only arm once recombinant FSH was added as a final step for anyone still not pregnant — a step-up strategy rather than a single procedure. The rate ratio between the two overall strategies was 1.01 (95% CI 0.81 to 1.24): equivalent. The multiple-pregnancy advantage was large and statistically significant in this same trial: an odds ratio of 0.11 (95% CI 0.01 to 0.86) favouring the electrocautery-first strategy. A separate, smaller randomised trial comparing LOD directly against three cycles of gonadotropins in women under 39 with a BMI under 35 and confirmed clomiphene resistance at a tertiary fertility clinic found closely matched cumulative pregnancy rates at 6 months — 28% with LOD versus 33% with gonadotropins — with three miscarriages in each group and no statistically significant difference between them.

Read together, these four independent trials point the same direction: LOD does not clearly out-perform gonadotropins on live birth, but it does not clearly under-perform them either once enough time and enough cycles are allowed, and it consistently produces fewer multiple pregnancies — the complication gonadotropin injections are hardest to fully control. What gonadotropin injections for PCOS actually involve, including their own monitoring burden and OHSS risk, is covered on their own page.

What Does the Guideline Say About Who Ovarian Drilling Is Used For?

The 2023 international guideline states that laparoscopic ovarian surgery “could be” second-line therapy for women with anovulatory PCOS who have confirmed clomiphene resistance and no other identified cause of infertility — language the guideline itself grades as a weak recommendation built on low-quality evidence, not a strong or routine one. The same guideline names three specific factors a clinician is instructed to weigh before offering it: the comparative cost of the procedure against the alternative, the surgical expertise required to perform it safely, and the fact that both intraoperative and postoperative risks are higher in women above a healthy weight. None of the trials above describe LOD as something to request; they describe a population it has been tested in, and a set of trade-offs a surgeon and patient weigh together once that population match is confirmed by a clinician — not a self-selected next step.

What Are the Real Surgical Risks?

Anaesthesia, infection, and adhesion formation are the three risks the Cochrane review names explicitly as the reason ovarian drilling is not a decision to make lightly, even though it is usually done as day surgery. General anaesthesia carries its own small, separate risk profile independent of PCOS — nausea, a sore throat from intubation, and grogginess for the rest of the day are the common, expected effects, while a genuine anaesthetic complication is rare but is the reason a pre-operative assessment happens at all. Infection after laparoscopic surgery is uncommon, and the recognisable signs are a fever above 38°C, spreading redness or discharge at a port-site incision, or pain that gets worse rather than better after the first couple of days — not the same as the ordinary shoulder-tip pain and abdominal bloating that come from the gas used to inflate the abdomen during any laparoscopy, which typically resolve within a few days on their own.

Adhesion formation is the risk most specific to this procedure, because it is the same complication that ended open ovarian wedge resection as a treatment. In a study that performed a second-look laparoscopy on 50 of 199 women who had undergone ovarian electrocautery, new adhesions around the ovary were found in 19.3% of cases, falling to 16.6% when the surgeon used abdominal lavage and artificial ascites at the end of the original procedure. Ovarian adhesions are frequently silent — most affected women had no symptom that would have flagged one, which is exactly why it took a second surgery to find them. The concern is mechanical: adhesions around the ovary and fallopian tube can, in principle, interfere with the tube’s ability to pick up an egg after ovulation, which is why the finding is tracked at all rather than treated as routine.

Does Ovarian Drilling Reduce Ovarian Reserve?

Serum anti-Müllerian hormone (AMH) — the standard blood marker of ovarian reserve — fell by a weighted mean of 2.13 ng/mL (95% CI 1.30 to 2.97) after LOD, across a 2017 meta-analysis pooling seven eligible studies and 442 women, and the decline held up consistently across every subgroup analysed by follow-up duration, AMH test kit, whether one or both ovaries were treated, and how much energy was applied during surgery. That is a large, statistically robust, and mechanistically unsurprising finding — the procedure works by destroying ovarian tissue on purpose — and it is the honest reason “diminished ovarian reserve” comes up as a concern with this procedure specifically, in a way it does not with an oral or injectable medication.

What the same meta-analysis does not resolve is what that drop actually means. Its own authors state plainly that it remains uncertain whether the decline reflects real, lasting damage to the pool of remaining eggs, or simply a normalisation of an AMH level that starts out elevated in PCOS because of the excess small follicles the condition itself produces — distinguishing the two requires longer-term studies that, as of that 2017 review, had not been done. This is one of the more honest gaps in the evidence: a real, repeatedly measured hormonal change, attached to a clinical significance nobody has yet nailed down.

Is the Improvement From Ovarian Drilling Permanent?

Regular menstrual cycles rose from 8% before surgery to 67% within the first year after LOD, then fell back to 37% at one to three years, before partially recovering to 55% at four to nine years, in a longitudinal study of 116 women who underwent LOD between 1991 and 1999, compared against 34 untreated anovulatory PCOS women diagnosed in the same window. No, the improvement is not permanent for everyone — the honest shape of that answer is a curve, not a single number. Reproductive outcomes followed a similar early-then-later pattern: 54 of 110 women (49%) conceived spontaneously in the first year after surgery, and a further 42 women (38%) conceived during the medium- and long-term follow-up that came after. Among women with hirsutism and acne at baseline, only about 23% and 40% respectively still had a long-term improvement in those symptoms.

Who This Does Not Help

Ovarian drilling has no trial evidence behind it for anyone not already confirmed clomiphene-resistant — it is not a shortcut around trying an oral medication first. It is also not indicated for infertility caused by something other than anovulation: a blocked fallopian tube, a uterine structural problem, or a male-factor sperm issue will not be improved by a procedure aimed at ovarian androgen production, which is why the guideline restricts its recommendation to women with “no other infertility factor” identified. The baseline fertility work-up that rules these in or out is standard practice before any second-line option comes up, and this specific procedure is one piece of the site’s wider fertility coverage beyond it.

Women above a healthy weight carry a higher risk from the procedure itself, per the same guideline — a different consideration from whether it works, worth raising directly with a surgeon rather than assumed to apply equally to everyone. And anyone who places a high priority on preserving every available marker of ovarian reserve — planning multiple future pregnancies, or already facing a reduced egg count for another reason — is looking at a procedure whose defining trade-off, a real AMH decline of uncertain long-term consequence, is the specific concern to raise before choosing it over a non-surgical alternative.

Common questions